KRYS Live signals | Maximize Profits with Getagraph.com

SELL 55 min ago

@ $156.83

Issued: 25 Apr 2024 @ 13:04

Return: 0.21%

Previous signal: Apr 23 - 15:53

Previous signal: Buy

Return: -3.12 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 13:58):

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States...

Stats
Today's Volume	115 500
Average Volume	399 454
Market Cap	4.45B
EPS	$0 ( 2024-02-26 )
Next earnings date	( $0.280 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	392.90
ATR14	$3.86 (2.46%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-11	Krishnan Suma	Sell	2 146	Common Stock
2024-03-11	Krishnan Suma	Sell	2 254	Common Stock
2024-03-11	Krishnan Suma	Sell	5 109	Common Stock
2024-03-11	Krishnan Suma	Sell	8 002	Common Stock
2024-03-11	Krishnan Suma	Sell	2 816	Common Stock

INSIDER POWER
4.49
Last 100 transactions
Buy: 214 300 \| Sell: 194 377

Volume Correlation

Long: 0.38 (neutral)

Short: 0.84 (strong)

Signal:(72) Same movement expected

Krystal Biotech Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Krystal Biotech Inc Correlation - Currency/Commodity

-0.09
( neutral )

-0.07
( neutral )

-0.03
( neutral )

0.16
( neutral )

-0.26
( neutral )

0.39
( neutral )

Krystal Biotech Inc Financials

Annual	2023
Revenue:	$50.70M
Gross Profit:	$42.60M (84.02 %)
EPS:	$0.400

Q3	2023
Revenue:	$42.14M
Gross Profit:	$37.77M (89.61 %)
EPS:	$0.310

Q2	2023
Revenue:	$8.56M
Gross Profit:	$8.33M (97.39 %)
EPS:	$2.88

Q2	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.250

Financial Reports:

No articles found.

Krystal Biotech Inc

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.